These trials demonstrated that PARPi (olaparib, niraparib, rucaparib) significantly improved PFS in patients with high-grade ovarian cancer, both with and without BRCA1/2 mutations, compared to placebo. Here, BRCA1 is linked to ovarian carcinoma.